Timber Pharma gains on FDA fast-track tag for rare skin disorder therapy

Trex Wind-Down

28/04/2022 17:42

** Shares of drug developer  TMBR.A  rise 4.7% to $0.28 in
afternoon trade 
    ** TMBR says the U.S. FDA granted fast-track designation to
TMB-001, company's topical treatment for two rare skin disorders
 urn:newsml:reuters.com:*:nGNXbLFR7f
    ** The fast-track tag allows for more frequent meetings and
written communication from the FDA to discuss a drug's
development plan - co
     ** The drug is intended for patients with X-linked
recessive ichthyosis and autosomal recessive congenital
ichthyosis lamellar ichthyosis - severe subtypes of a disorder
which can lead to dry and scaling skin
    ** Co expects to launch late-stage clinical trial to
evaluate of TMB-001 within the next 60 days
    ** Stock down 26% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))